Literature DB >> 22580923

[Recurrent bladder cancer after BCG instillation therapy. Local therapy options?].

J M Laturnus1, D Jocham, M Sommerauer.   

Abstract

Patients with a so-called BCG failure (Bacillus Calmette-Guérin) constitute an inhomogeneous group of patients. Patients with BCG recurrence or BCG refractive tumors are real BCG failures. Therapeutic options are radical cystectomy and a conservative approach, depending on the individual risk of recurrence and progression. Intravesical chemotherapy with docetaxel or gemcitabine after BCG failure shows some promise whereas second line immunotherapy, the combination of BCG and interferon (INF)-α, is an effective regimen but results need to be confirmed. Device-assisted intravesical strategies, such as mitomycin-EMDA or chemohyperthermia are candidates to keep in mind for the near future. Finally, cystectomy results in the best disease-specific survival in patients with BCG failure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580923     DOI: 10.1007/s00120-012-2875-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  47 in total

1.  Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy.

Authors:  James M McKiernan; Puneet Masson; Alana M Murphy; Manlio Goetzl; Carl A Olsson; Daniel P Petrylak; Manisha Desai; Mitchell C Benson
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

2.  Defining bacillus Calmette-Guerin refractory superficial bladder tumors.

Authors:  Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2003-05       Impact factor: 7.450

3.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

Authors:  A Böhle; D Jocham; P R Bock
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

4.  Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.

Authors:  R Paroni; A Salonia; A Lev; L F Da Pozzo; G Cighetti; F Montorsi; P Rigatti; R Colombo
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

5.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

6.  Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3).

Authors:  Richard E Hautmann; Bjoern G Volkmer; Kilian Gust
Journal:  World J Urol       Date:  2009-03-25       Impact factor: 4.226

7.  Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder.

Authors:  A G van der Heijden; L A Kiemeney; O N Gofrit; O Nativ; A Sidi; Z Leib; R Colombo; R Naspro; M Pavone; J Baniel; F Hasner; J A Witjes
Journal:  Eur Urol       Date:  2004-07       Impact factor: 20.096

Review 8.  Management of BCG failures in superficial bladder cancer: a review.

Authors:  Johannes A Witjes
Journal:  Eur Urol       Date:  2006-01-24       Impact factor: 20.096

9.  Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.

Authors:  Brian L Gallagher; Fadi N Joudi; José L Maymí; Michael A O'Donnell
Journal:  Urology       Date:  2008-02       Impact factor: 2.649

10.  Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy.

Authors:  Barthold Ph Schrier; Maarten P Hollander; Bas W G van Rhijn; Lambertus A L M Kiemeney; J Alfred Witjes
Journal:  Eur Urol       Date:  2004-03       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.